Pediatric Glial Tumors

Pediatr Dev Pathol. 2022 Jan-Feb;25(1):46-58. doi: 10.1177/10935266211009101. Epub 2021 Apr 19.

Abstract

Pediatric glial tumors are unique from their adult counterparts. This important distinction is recognized and incorporated into the World Health Organization classification of central nervous system tumors and applies to both high- and low-grade gliomas, incorporating their specific molecular profiles. Molecular alterations in pediatric high-grade gliomas provide important prognostic information, for example in H3 K27M-mutant tumors. The integration of molecular information is also important for pediatric low-grade gliomas due to their overlapping morphologies and the prognostic and therapeutic implications of these molecular alterations. In this paper, we cover a variety of glial tumors, encompassing neoplasms with predominantly glial histology, astrocytic tumors, oligodendroglial tumors, and mixed glioneuronal tumors. Considering the complexity of this evolving field, the purpose of this article is to offer a practical approach to the diagnosis of pediatric gliomas, including the selection of the most appropriate molecular surrogate immunohistochemical stains, basic molecular studies, and more sophisticated techniques if needed. The goal is to reach a rapid, sound diagnosis, helping guide clinical decision-making regarding prognosis and potential therapies.

Keywords: glioma; immunohistochemistry; molecular pathology; neuropathology; pediatric; surg path; tumors.

MeSH terms

  • Adult
  • Brain Neoplasms* / diagnosis
  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / therapy
  • Child
  • Glioma* / diagnosis
  • Glioma* / genetics
  • Glioma* / therapy
  • Humans
  • Mutation
  • Neuroglia
  • Prognosis